HealZen Therapeutics (‘HealZen’) and PTM Biolabs Co., Ltd. (‘PTM BIO’) have recently reached a strategic partnership agreement to establish a long-term comprehensive strategic partnership in the field of targeted protein degradation (TPD) target discovery, drug development, and other aspects.

In recent years, targeted protein degradation technology (represented by PROTAC) has been regarded as a disruptive technology for small molecule drug development. This technology uses the existing protein regulation mechanism ubiquitin-proteasome system (UPS) in cells to degrade target proteins, thereby achieving the purpose of treating related diseases. As an important support for the rapid development of modern life science technology, proteomics helps to find reliable drug targets, explore the interaction between drugs and targets, clarify drug regulation mechanisms, and has significance in new target discovery, drug development, and other areas of life and health.

This partnership between HealZen and PTM BIO will make full use of their unique small molecule DaMLib® library, DaTProD® platform, and ‘Integrated Proteomics Platform’ to jointly lead a win-win cooperation based on the TPD field, and achieve a breakthrough in targeted protein degradation technology. 

About PTM BIO
PTM BIO is a leading innovator in the application and development of proteomics technology in China, with a research background in the forefront of ‘proteomics-precision medicine’ research fields. It has formed an innovative business model integrating R&D, production, and service, and has built the largest ‘integrated proteomics platform’ in China, including proteomics technology platform, epigenetics technology platform, biomarker discovery platform, high-quality antibody development platform, diagnostic reagent kit platform, and big data analysis platform. The company was founded in December 2010, headquartered in Hangzhou, with a subsidiary in Chicago, USA.